Navigation Links
Labrys Biologics Announces Key Executive Appointments
Date:3/18/2013

onin gene-related peptide (CGRP), a validated target in migraine. RN-307 has successfully completed Phase 1 trials in more than 74 patients. RN-307 was originally discovered and developed by Rinat Pharmaceuticals, which was acquired by Pfizer in 2006.

About Labrys Biologics
Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys' lead candidate, RN-307, is an anti-CGRP monoclonal antibody for the treatment of chronic migraine which has completed Phase 1. Founded in late 2012, Labrys is backed by venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures. 


'/>"/>
SOURCE Labrys Biologics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
2. Synthetic Biologics to Present at the 2013 BIO CEO & Investor Conference
3. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
4. ChromaDex® Announces Financial Results for the Year Ended 2011
5. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
6. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
7. Global Information Inc. Announces Discounted Conference Registration For Bio-IT World Asia and Biodetection Technologies 2012
8. Virginia Tech announces 2012 football helmet ratings; 2 more added to the 5-star mark
9. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
10. BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
11. Mass. Eye and Ear announces Curing Kids Fund grant recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... treatment for a brain infection caused by fungus could now ... to study by University of Liverpool scientists. , Cryptococcus ... fatal but are relatively neglected in medical research. They ... Australasia and South East Asia and mainly affect people with ... a year. , The University research team has tested the ...
(Date:4/24/2014)... the largest river turtle in North America, weighing in ... century. Now researchers from Florida and the University of ... but three. , Examining museum specimens and wild ... ancient reptile. , Once heavily hunted for turtle meat ... Turtle Soup in the 1960s the riverine populations ...
(Date:4/23/2014)... chronic inflammatory disorders among people of lower socioeconomic status ... to the microbes that thrive in rural environments, according ... in the journal Clinical & Experimental Immunology , ... less access to green spaces may be more apt ... system dysfunction. , When our immune systems are working ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3
... Mellon University,s Philip R. LeDuc and his collaborators in ... a protein that could ultimately unlock the mystery of ... role in the mechanics of biological processes in people. ... function of a protein that helps control cell behavior ...
... Reunion in the Indian Ocean and collaborating with researchers at ... sensitive night cameras to capture the first known occurrence of ... only is this the first time this behaviour has been ... who are better known for eating plants but ...
... number of scientists are merging methods and results from different ... team of researchers in a recent issue of Evolution ... new data, however, researchers who want to analyze previous findings ... the authors say. In a commentary piece in the journal ...
Cached Biology News:Carnegie Mellon's Philip LeDuc discovers new protein function 2First known instance of a cricket as an orchid pollinator captured on film by Kew scientist 2Biologists merge methods, results from different disciplines to find new meaning in old data 2Biologists merge methods, results from different disciplines to find new meaning in old data 3
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... , EMERYVILLE, Calif., Aug. 6 Onyx Pharmaceuticals, ... to sell an aggregate of four million shares of its common stock ... million aggregate principal amount of its 4.00% convertible senior notes due 2016 ... options to purchase up to an additional 600,000 shares of its common ...
... , ALBANY, Ore., Aug. 6 Synthetech, Inc. (OTC ... of fiscal 2010, which ended June 30, 2009. Revenue for ... of $4.9 million in the first quarter of fiscal 2009. ... operating income of $314,000 for the same period last year. ...
... Md., Aug. 6 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ... of clinical-stage product candidates for central nervous system disorders, today announced ... on Monday, August 10, 2009, before the market opens. A full ... , , Mihael H. Polymeropoulos, M.D., President and ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 2
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
... meet the needs of the ... medium supports fast cell growth ... while maintaining high cell viability ... using the Baculovirus Expression Vector ...
Mol wt: average mol wt12,360.96 Da by calculation...
Biology Products: